Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Gets Canadian Clearance for Respiratory Virus Panel

NEW YORK (GenomeWeb News) – Luminex said today that Health Canada has cleared for marketing the firm’s xTAG Respiratory Virus Panel, which detects 18 respiratory viruses and subtypes that are responsible for the majority of respiratory viral infections.
 
The panel is based on Luminex’s xMAP multiplex technology and was developed by the firm’s Toronto-based subsidiary, Luminex Molecular Diagnostics.
 
Among the viruses that the xTAG RVP detects are adenovirus, coronavirus, enterovirus, influenza, metapneumovirus, parainfluenza, and respiratory syncytial virus. It also detects subtypes of these viruses.
 
"Because it quickly and simultaneously detects the presence or absence of 18 different virus types and subtypes, xTAG RVP allows physicians to diagnose an infection and make appropriate management decisions,” said James Mahony, director of the Regional Virology Laboratory at St. Joseph's Healthcare, who helped develop the test. “It can detect viruses that cannot be detected with conventional tests and can accurately diagnose patients infected with multiple respiratory viruses."
 
The xTAG RVP is already cleared for marketing in Europe and the US.
 

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.